Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dalia L Rotstein

Showing results (11-20 of 43) with videos related to

Pageof 5
Sort By:
Frontiers in Neurology|June 1, 2022
Chronic Cognitive Impairment in AQP4+ NMOSD With Improvement in Cognition on Eculizumab: A Report of Two CasesGeorges Saab, David G Munoz, Dalia L Rotstein
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|May 21, 2010
Increasing use of disease modifying drugs for MS in CanadaDalia L Rotstein, Muhammad Mamdani, Paul W O'Connor
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|March 1, 2002
Addressing the challenges of queuesDalia L Rotstein, David A Alter, Dalis L Rotstein
CNS Drugs|July 18, 2025
Multiple Sclerosis in People of Diverse Racial and Ethnic Backgrounds: Presentation, Disease Course, and Interactions with Disease-Modifying TherapyJulia Li, Nandita Vas, Lilyana Amezcua, et al.
Headache|May 16, 2014
A case report of cavernous sinus syndrome in a patient with Takayasu's arteritisDalia L Rotstein, Felix J Tyndel, David F Tang-Wai
Frontiers in Neurology|March 29, 2024
Myelin oligodendrocyte glycoprotein antibody titers by fixed cell-based assay: positive predictive value and impact of sample collection timingAdrian Budhram, Dalia L Rotstein, Liju Yang, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 12, 2026
Ofatumumab and enteroviral encephalitis: a severe infectious complication as a class effect with anti-CD20 therapiesDalia L Rotstein, Sheliza Halani, Peter Vadas, et al.
Therapeutic Advances in Neurological Disorders|May 26, 2021
A window into the future? MRI for evaluation of neuromyelitis optica spectrum disorder throughout the disease courseJacqueline M Solomon, Friedemann Paul, Claudia Chien, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 18, 2019
CNS demyelination after initiating the tyrosine kinase inhibitor imatinib: A report of two casesDalia L Rotstein, Katherine Sawicka, Aditya Bharatha, et al.
The Lancet. Neurology|March 22, 2025
Multiple sclerosis and COVID-19: interactions and unresolved issuesAna Zabalza, Alan Thompson, Dalia L Rotstein, et al.
Pageof 5

Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
Frontiers in Neurology|June 1, 2022
Chronic Cognitive Impairment in AQP4+ NMOSD With Improvement in Cognition on Eculizumab: A Report of Two CasesGeorges Saab, David G Munoz, Dalia L Rotstein
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|May 21, 2010
Increasing use of disease modifying drugs for MS in CanadaDalia L Rotstein, Muhammad Mamdani, Paul W O'Connor
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|March 1, 2002
Addressing the challenges of queuesDalia L Rotstein, David A Alter, Dalis L Rotstein
CNS Drugs|July 18, 2025
Multiple Sclerosis in People of Diverse Racial and Ethnic Backgrounds: Presentation, Disease Course, and Interactions with Disease-Modifying TherapyJulia Li, Nandita Vas, Lilyana Amezcua, et al.
Headache|May 16, 2014
A case report of cavernous sinus syndrome in a patient with Takayasu's arteritisDalia L Rotstein, Felix J Tyndel, David F Tang-Wai
Frontiers in Neurology|March 29, 2024
Myelin oligodendrocyte glycoprotein antibody titers by fixed cell-based assay: positive predictive value and impact of sample collection timingAdrian Budhram, Dalia L Rotstein, Liju Yang, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 12, 2026
Ofatumumab and enteroviral encephalitis: a severe infectious complication as a class effect with anti-CD20 therapiesDalia L Rotstein, Sheliza Halani, Peter Vadas, et al.
Therapeutic Advances in Neurological Disorders|May 26, 2021
A window into the future? MRI for evaluation of neuromyelitis optica spectrum disorder throughout the disease courseJacqueline M Solomon, Friedemann Paul, Claudia Chien, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 18, 2019
CNS demyelination after initiating the tyrosine kinase inhibitor imatinib: A report of two casesDalia L Rotstein, Katherine Sawicka, Aditya Bharatha, et al.
The Lancet. Neurology|March 22, 2025
Multiple sclerosis and COVID-19: interactions and unresolved issuesAna Zabalza, Alan Thompson, Dalia L Rotstein, et al.
Pageof 5